# An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

> **NCT02319460** · — · COMPLETED · sponsor: **CSL Behring** · enrollment: 2238 (actual)

## Conditions studied

- Hemorrhage

## Interventions

- **BIOLOGICAL:** Kcentra®
- **BIOLOGICAL:** Plasma

## Key facts

- **NCT ID:** NCT02319460
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-24
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 2238 (ACTUAL)
- **Last updated:** 2021-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319460, "An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02319460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*